Adjuvant chemotherapy is associated with better oncological outcomes after ALPPS for colorectal liver metastases
Updates in Surgery · 2024
DOI: 10.1007/s13304-024-01835-1 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Updates in Surgery, 2024. Verfasst von Fernando A Alvarez und 6 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Service, Hepato-Pancreato-Biliary Surgery Section and Liver Transplant Unit, Hospital Italiano de Buenos Aires, Juan D. Perón 4190, C…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Hepatectomy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
ALPPS enables complete tumor resection in a shorter interval and a larger number of patients than classic two-stage hepatectomies. However, there is little evidence regarding long-term outcomes in patients with colorectal liver metastases (CLM). This study aims to evaluate the short and long-term outcomes of ALPPS in patients with CRM. Single-cohort, prospective, observational study. Patients with unresectable CLM due to insufficient liver remnant who underwent ALPPS between June 2011 and June 2021 were included. Of 32 patients treated, 21 were male (66%) and the median age was 56 years (range = 29-81). Both stages were completed in 30 patients (93.7%), with an R0 rate of 75% (24/32). Major morbidity was 37.5% and the mortality nil. Median overall survival (OS) and recurrence-free survival (RFS) were 28.1 and 8.8 months, respectively. The 1-3, and 5-year OS was 86%, 45%, and 21%, and RFS was 42%, 14%, and 14%, respectively. The only independent risk factor associated with poor RFS (5.7 vs 11.6 months; p = 0.038) and OS (15 vs 37 months; p = 0.009) was not receiving adjuvant chemotherapy. KRAS mutation was associated with worse OS from disease diagnosis (24.3 vs. 38.9 months; p = 0.025). ALPPS is associated with favorable oncological outcomes, comparable to traditional strategies to increase resectability in patients with CLM and high tumor burden. Our results suggest for the first time that adjuvant chemotherapy is independently associated with better short- and long-term outcomes after ALPPS. Selection of patients with KRAS mutations should be performed with caution, as this could affect oncological outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- General Surgery Service, Hepato-Pancreato-Biliary Surgery Section and Liver Transplant Unit, Hospital Italiano de Buenos Aires, Juan D. Perón 4190, C1181AC, Buenos Aires, Argentina.
- General Surgery Service, Hepato-Pancreato-Biliary Surgery Section and Liver Transplant Unit, Hospital Italiano de Buenos Aires, Juan D. Perón 4190, C1181AC, Buenos Aires, Argentina. eduardo.desantibanes@hospitalitaliano…
Zitieren
APA
Alvarez, F. A., Ardiles, V., Chara, C., de Santibañes, M., Sánchez Clariá, R., Pekolj, J., & de Santibañes, E. (2024). Adjuvant chemotherapy is associated with better oncological outcomes after ALPPS for colorectal liver metastases. Updates in Surgery. https://doi.org/10.1007/s13304-024-01835-1
Vancouver
Alvarez FA, Ardiles V, Chara C, de Santibañes M, Sánchez Clariá R, Pekolj J, et al. Adjuvant chemotherapy is associated with better oncological outcomes after ALPPS for colorectal liver metastases. Updates in Surgery. 2024. doi:10.1007/s13304-024-01835-1
BibTeX
@article{Alvarez2024,
author = {Alvarez, Fernando A and Ardiles, Victoria and Chara, Camila and de Santibañes, Martin and Sánchez Clariá, Rodrigo and Pekolj, Juan and de Santibañes, Eduardo},
title = {Adjuvant chemotherapy is associated with better oncological outcomes after ALPPS for colorectal liver metastases},
journal = {Updates in Surgery},
year = {2024},
doi = {10.1007/s13304-024-01835-1}
}
EUVIMED